Hypertension Trial, Recruiting NCT05479461 Sponsor: Stanford University Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT05479461
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between the ages of 30 and 90 years old
  • People who own a smartphone
  • People whose blood pressure reading taken in a clinic or doctor's office is 140 mmHg or higher (the top number)
  • People who are currently taking two or fewer blood pressure-lowering medications
  • People whose doctor is able to add or increase the dose of at least two different types of blood pressure medications from a specific list of medication classes (confirm with trial site)
  • People who speak English or Spanish

Who may not be able to join:

  • People who have heart failure where the heart is pumping weakly (confirmed by a specific heart function measurement)
  • People who have very severe kidney disease (confirm with trial site)
  • People who are on dialysis or another treatment that replaces kidney function
  • People who are pregnant
  • People who have had a heart attack or stroke in the past 6 months
  • People who have been hospitalised for a severe high blood pressure emergency in the past 6 months
  • People who have previously received a transplanted organ (such as a kidney, heart, or liver)
  • People whom the trial investigators decide should not participate, based on their medical judgement
  • People who are already enrolled in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul J Wang, MD, Stanford University

Phone: (650) 723-9363

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 June 2023
Est. completion
15 September 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Defined Daily Dose (DDD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov